SCYNEXIS Inc (SCYX) stock
SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3071% below fair value
$2.91−0.30 (-9.35%)
Close on Nov 16, 2026Market cap $28.95MP/E –Yield –
Scynexis ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Scynexis's ebitda for the twelve months ending Dec 31, 2024 was -$37.12M, down 150.7% year over year. For fiscal 2024 it was -$37.12M, down 150.7% from the year before. The highest annual figure on record is $73.25M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$37.12M | -150.7% |
| FY2023 | Dec 31, 2023 | $73.25M | – |
| FY2022 | Dec 31, 2022 | -$85.15M | – |
| FY2021 | Dec 31, 2021 | -$60.46M | – |
| FY2020 | Dec 31, 2020 | -$51.04M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$8.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.24M | -107.9% |
| Q1 FY2024 | Mar 31, 2024 | -$9.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.94M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.95M | – |
| Q2 FY2023 | Jun 30, 2023 | $116.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.65M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.58M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.39M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.45M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.57M | – |
See a number that looks wrong?